Cardiovascular Drugs Practice Questions

Q: All are true about Carvedilol except?

It is a cardioselective beta-blocker. **Explanation:** **Why Option C is the correct answer (The "Except" statement):** Carvedilol is a **non-selective beta-blocker** (blocks both $\beta_1$ and $\beta_2$ receptors) that also possesses **$\alpha_1$-blocking** activity. [1] It does not exhibit cardioselectivity. Cardioselective beta-blockers (like Metoprolol, Bisoprolol, and Atenolol) primarily target $\beta_1$ receptors. Carvedilol’s additional $\alpha_1$ blockade leads to peripheral vasodilation, which reduces afterload—a distinct advantage in managing heart failure. **Analysis of other options:** * **Option A:** Carvedilol is a first-line agent in **Chronic Congestive Heart Failure (CHF)**. It reduces remodeling, decreases mortality, and improves ejection fraction. [3] * **Option B:** Beyond receptor blockade, Carvedilol has unique **antioxidant** (scavenges free radicals) and **anti-inflammatory** properties, which protect the myocardium from oxidative stress. [1] * **Option D:** In CHF, beta-blockers must be started at **"low dose and titrated slowly"** (Start low, go slow). This prevents acute decompensation due to the initial negative inotropic effect, allowing the heart to adapt to the long-term benefits of sympathetic blockade. **High-Yield Clinical Pearls for NEET-PG:** * **Generation:** Carvedilol is a **3rd generation** (vasodilatory) beta-blocker. [2] * **Lipophilicity:** It is highly lipid-soluble and undergoes extensive first-pass metabolism. * **Metabolic Profile:** Unlike older beta-blockers, Carvedilol is metabolically neutral or may improve insulin sensitivity. * **FDA Approved for CHF:** Only three beta-blockers are proven to reduce mortality in CHF: **Carvedilol, Bisoprolol, and Metoprolol Succinate** (long-acting). [2], [3]

Q: Drugs associated with clinically useful or physiologically important positive inotropic effects include all of the following except?

Enalapril. **Explanation:** The core of this question lies in understanding the mechanism of **Inotropy** (the force of myocardial contraction). Positive inotropic agents increase the concentration of intracellular calcium or the sensitivity of contractile proteins to calcium, thereby increasing cardiac output. **Why Enalapril is the Correct Answer:** **Enalapril** is an **ACE Inhibitor**. Its primary mechanism involves inhibiting the conversion of Angiotensin I to Angiotensin II and preventing the breakdown of bradykinin. This leads to systemic vasodilation (decreased afterload) and reduced salt/water retention (decreased preload). While Enalapril is a cornerstone in treating Heart Failure because it reduces cardiac workload and prevents remodeling, it has **no direct positive inotropic effect** on the myocardium. **Analysis of Incorrect Options:** * **Amrinone (and Milrinone):** These are **PDE-3 inhibitors**. They prevent the breakdown of cAMP in cardiac muscle, leading to increased calcium influx and increased contractility (Inodilators). * **Digoxin:** A **Cardiac Glycoside** that inhibits the Na+/K+ ATPase pump. This indirectly leads to an increase in intracellular calcium via the Na+/Ca2+ exchanger, resulting in a potent positive inotropic effect. * **Dobutamine:** A selective **Beta-1 agonist**. It stimulates Gs-coupled receptors to increase cAMP, directly enhancing myocardial contractility. **NEET-PG High-Yield Pearls:** * **Inodilators:** Drugs like Milrinone and Levosimendan provide both positive inotropy and vasodilation. * **Levosimendan:** Acts as a **Calcium sensitizer**; it increases contractility without increasing myocardial oxygen demand significantly. * **ACE Inhibitors:** Known as "Life-prolonging drugs" in heart failure, but they are **not** inotropes. * **Digoxin Toxicity:** Characterized by xanthopsia (yellow vision) and various arrhythmias (most specific being Atrial Tachycardia with AV block).

Q: Which of the following anti-angina drugs acts by inhibition of long-chain 3-ketoacyl coenzyme A thiolase?

Trimetazidine. ### Explanation **Correct Option: A. Trimetazidine** Trimetazidine is a **pFOX inhibitor** (partial fatty acid oxidation inhibitor). It works by inhibiting the enzyme **long-chain 3-ketoacyl coenzyme A thiolase (3-KAT)**. * **Mechanism:** Under normal conditions, the heart derives energy from fatty acid oxidation, which requires more oxygen. By inhibiting 3-KAT, Trimetazidine shifts myocardial metabolism from fatty acid oxidation to **glucose oxidation**. * **Benefit:** Glucose oxidation is more oxygen-efficient, allowing the heart to produce more ATP per molecule of oxygen consumed, thereby protecting the myocardium during ischemic episodes without affecting heart rate or blood pressure. **Incorrect Options:** * **B. Ivabradine:** Acts by selectively inhibiting the **funny current ($I_f$)** in the sinoatrial (SA) node. It reduces heart rate without affecting myocardial contractility or BP. * **C. Ranolazine:** Primarily acts by inhibiting the **late inward sodium current ($I_{Na}$)** in cardiomyocytes. This prevents calcium overload and improves diastolic relaxation. * **D. Nicorandil:** A dual-action drug that acts as a **K+ATP channel opener** (causing arterial vasodilation) and a **Nitric Oxide (NO) donor** (causing venodilation). **High-Yield Clinical Pearls for NEET-PG:** * **Trimetazidine** is often used as add-on therapy in stable angina; however, it is contraindicated in patients with **Parkinson’s disease** as it may worsen extrapyramidal symptoms. * **Ivabradine** is specifically indicated in patients with stable angina who have a contraindication to Beta-blockers, provided they are in **sinus rhythm**. * **Nicorandil** can cause a unique side effect: **persistent mucosal ulcerations** (e.g., oral, anal, or GI ulcers).

Q: Which of the following antihypertensive drugs inhibits the vesicular uptake of norepinephrine?

Reserpine. ### Explanation **Correct Option: C. Reserpine** Reserpine is an alkaloid derived from *Rauwolfia serpentina*. Its primary mechanism of action is the **irreversible inhibition of the Vesicular Monoamine Transporter (VMAT-2)**. * **Mechanism:** Under normal conditions, VMAT-2 transports free norepinephrine (NE), dopamine, and serotonin from the cytoplasm into storage vesicles. By blocking VMAT-2, reserpine prevents the vesicular uptake and storage of these neurotransmitters. * **Result:** The unprotected NE in the cytoplasm is degraded by the enzyme **Monoamine Oxidase (MAO)**, leading to a profound depletion of catecholamines in sympathetic nerve terminals, which results in a decrease in blood pressure and heart rate. **Analysis of Incorrect Options:** * **A. Propranolol:** A non-selective **beta-blocker** ($β_1$ and $β_2$). it acts by antagonizing adrenergic receptors, not by affecting neurotransmitter storage or uptake. * **B. Prazosin:** A selective **alpha-1 ($α_1$) blocker**. It causes vasodilation by blocking postsynaptic receptors on vascular smooth muscle. * **D. Guanethidine:** This drug inhibits the **release** of norepinephrine from the nerve terminal and displaces NE from vesicles, but it does not primarily act by inhibiting the VMAT-2 uptake pump like reserpine. **High-Yield Clinical Pearls for NEET-PG:** * **Depression Warning:** Because reserpine also depletes serotonin and dopamine in the CNS, it is notorious for causing **severe mental depression** and is contraindicated in patients with a history of depressive illness. * **Gastrointestinal Effects:** By depleting sympathetic tone, it leads to parasympathetic dominance, causing increased gastric acid secretion (risking peptic ulcers) and diarrhea. * **VMAT-1 vs VMAT-2:** VMAT-1 is found in neuroendocrine cells (adrenal medulla), while **VMAT-2** is the primary target in the CNS and peripheral postganglionic neurons.

Q: What is the primary effect of Nicotinic acid?

Increases HDL. **Explanation:** **Nicotinic Acid (Niacin)** is a potent lipid-lowering agent. Its **primary and most significant effect is increasing HDL levels** (by 15–35%), making it the most effective drug currently available for this purpose. 1. **Why Option A is Correct:** Niacin increases HDL levels by decreasing the fractional fractional clearance of apoA-I (the primary apolipoprotein of HDL) in the liver. This prolongs the half-life of HDL particles, enhancing reverse cholesterol transport. 2. **Why Options B, C, and D are Incorrect:** * **Option B:** Niacin actually **decreases** triglyceride synthesis by inhibiting diacylglycerol acyltransferase-2 (DGAT2) in the liver. * **Option C:** While Niacin can be used as an adjunct, **Statins** are the first-line treatment for Type II hyperlipoproteinemia (Hypercholesterolemia). Niacin is more specifically indicated for Type IV and V (Hypertriglyceridemia). * **Option D:** Niacin **inhibits the lipolysis of triglycerides** in adipose tissue by inhibiting the enzyme hormone-sensitive lipase (HSL). This reduces the flow of free fatty acids to the liver, thereby decreasing VLDL production, rather than decreasing VLDL hydrolysis. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** Acts via G protein-coupled receptors (GPR109A) to inhibit hormone-sensitive lipase in adipose tissue. * **Side Effects:** The most common side effect is **cutaneous flushing** (mediated by Prostaglandin $D_2$ and $E_2$; prevented by Aspirin). * **Metabolic Complications:** Can cause **hyperuricemia** (precipitating gout) and **hyperglycemia** (impaired glucose tolerance), so it must be used cautiously in diabetic patients. * **Acanthosis Nigricans:** Niacin therapy is a known pharmacological cause of this skin condition.

Q: Which ECG findings represent a characteristic manifestation of digitalis toxicity?

Atrial tachycardia with variable block. **Explanation:** **Atrial tachycardia with variable AV block** is considered the most characteristic (pathognomonic) arrhythmia of digitalis toxicity. This occurs due to the dual action of Digoxin: 1. **Increased Automaticity:** Digoxin inhibits the Na+/K+ ATPase pump, leading to intracellular Calcium overload, which increases the firing rate of atrial ectopic foci (causing tachycardia). 2. **Increased Vagomimetic Effect:** Digoxin increases vagal tone, which slows conduction through the AV node (causing the block). The combination of a rapid atrial rate with a blocked conduction is a classic "signature" of Digoxin overdose. **Analysis of Incorrect Options:** * **A & B (ST-segment depression and T-wave inversion):** These are common ECG changes seen with **therapeutic** doses of Digoxin (often described as a "reverse tick" or "scooped" ST segment). While present in toxicity, they are not specific to it. * **C (Atrial flutter):** Digoxin is actually used to treat atrial flutter by increasing the AV block; it is rarely caused by the drug itself. **High-Yield Clinical Pearls for NEET-PG:** * **Most Common Arrhythmia:** Ventricular Bigeminy (PVCs). * **Most Characteristic Arrhythmia:** Atrial tachycardia with block. * **Most Common Cause of Death:** Ventricular Fibrillation. * **Electrolyte Triggers:** Hypokalemia, Hypomagnesemia, and Hypercalcemia predispose to toxicity. * **Antidote:** Digoxin-specific antibody fragments (DigiFab/Digibind). * **Visual Side Effect:** Xanthopsia (yellowish-green vision).

Q: Activation of which of the following receptors causes vasoconstriction?

ETa receptor. **Explanation:** The correct answer is **D. ETa receptor**. **1. Why ETa receptor is correct:** Endothelin-1 (ET-1) is one of the most potent endogenous vasoconstrictors known [2]. It acts primarily through two G-protein coupled receptors: **ETa** and **ETb**. * **ETa receptors** are located on vascular smooth muscle cells [3]. Their activation leads to an increase in intracellular calcium, resulting in profound and prolonged **vasoconstriction** [1]. * (Note: ETb receptors on the endothelium actually cause vasodilation via NO release, but ETa is the dominant mediator of constriction). **2. Why the other options are incorrect:** * **Nm receptor (Option A):** These are nicotinic receptors found at the **Neuromuscular Junction**. Their activation leads to skeletal muscle contraction, not vascular smooth muscle action. * **M3 receptor (Option B):** While M3 receptors are present on vascular endothelium, their activation triggers the release of Nitric Oxide (EDRF), which leads to **vasodilation**. (In the absence of endothelium, they can cause constriction, but physiologically they are associated with dilation). * **Nn receptor (Option C):** These are nicotinic receptors found in **Autonomic Ganglia** and the adrenal medulla. While they mediate neurotransmission, they do not directly cause vasoconstriction; any vascular effect would be indirect via sympathetic ganglionic stimulation. **3. Clinical Pearls for NEET-PG:** * **Bosentan:** A dual ETa and ETb receptor antagonist used in the treatment of **Pulmonary Arterial Hypertension (PAH)** [4]. * **Ambrisentan:** A selective ETa receptor antagonist also used for PAH. * **High-Yield Constrictors:** Remember the "Big Three" for exams: **Alpha-1 (α1)**, **Angiotensin II (AT1)**, and **Endothelin (ETa)**. * **M3 Paradox:** M3 activation causes *contraction* of all smooth muscles (gut, bladder, bronchi) **EXCEPT** vascular smooth muscle, where it causes *relaxation* (via NO).

Q: What is the drug available for the treatment of resistant cases of atrial fibrillation?

Amiodarone. **Explanation:** **Amiodarone** is the drug of choice for resistant or refractory atrial fibrillation (AF) due to its unique pharmacological profile. It is a Class III antiarrhythmic that primarily blocks potassium channels, prolonging the action potential duration and effective refractory period. However, it also possesses Class I (sodium channel), Class II (beta-blocking), and Class IV (calcium channel) activities. This "broad-spectrum" effect makes it highly effective in maintaining sinus rhythm when other agents fail, especially in patients with structural heart disease or heart failure. **Why other options are incorrect:** * **Quinidine (Class IA):** While it can convert AF to sinus rhythm, it is rarely used today due to significant side effects (cinchonism, thrombocytopenia) and the risk of "Quinidine syncope" caused by Torsades de Pointes. * **Propranolol (Class II):** Beta-blockers are excellent for **rate control** in AF, but they are generally not effective for converting resistant AF back to sinus rhythm (rhythm control). * **Digoxin:** It is used for rate control in AF, particularly in sedentary patients or those with heart failure. However, it is ineffective for rhythm conversion and does not work well during high-sympathetic states (like exercise). **Clinical Pearls for NEET-PG:** * **Drug of Choice:** Amiodarone is the preferred drug for AF in patients with **congestive heart failure (CHF)** or myocardial infarction. * **Side Effects:** High-yield for exams! Watch for pulmonary fibrosis, thyroid dysfunction (due to high iodine content), corneal microdeposits, and "blue-gray" skin discoloration. * **Monitoring:** Patients on long-term Amiodarone require periodic Liver Function Tests (LFTs), Thyroid Function Tests (TFTs), and Chest X-rays.

Q: Which of the following statements regarding carvedilol is incorrect?

Its oral bioavailability is approximately 80%.. ### Explanation **Why Option B is the correct answer (Incorrect Statement):** Carvedilol undergoes **extensive first-pass metabolism** in the liver. Consequently, its oral bioavailability is quite low, approximately **25% to 30%**, not 80%. This is a high-yield pharmacokinetic property often tested in competitive exams to differentiate it from other beta-blockers. **Analysis of Other Options:** * **Option A:** Carvedilol is a **non-selective beta-blocker** (blocks $\beta_1$ and $\beta_2$) that also possesses **$\alpha_1$-blocking** activity. The ratio of $\alpha$ to $\beta$ blockade is approximately 1:10. This dual action leads to peripheral vasodilation along with reduced heart rate. * **Option C:** It is unique among beta-blockers for its **antioxidant and anti-proliferative properties**. It scavenges free radicals and inhibits lipid peroxidation, which helps prevent vascular smooth muscle hypertrophy and remodeling. * **Option D:** Carvedilol is a cornerstone in the management of **Congestive Heart Failure (CHF)**. By reducing afterload (via $\alpha_1$ blockade) and protecting the myocardium from catecholamine-induced toxicity, it significantly reduces mortality and hospitalization in CHF patients (as proven in the COPERNICUS and CAPRICORN trials). **Clinical Pearls for NEET-PG:** * **Lipophilicity:** Carvedilol is highly lipophilic. * **Metabolism:** It is primarily metabolized by CYP2D6 and CYP2C9; genetic polymorphisms in these enzymes can affect drug levels. * **The "Big Three" in CHF:** Carvedilol, Metoprolol succinate, and Bisoprolol are the three beta-blockers specifically proven to reduce mortality in chronic heart failure. * **Contraindication:** Like other non-selective beta-blockers, it should be avoided in patients with bronchial asthma due to $\beta_2$ blockade.

Question 1

All are true about Carvedilol except?

Accepted Answer

It is a cardioselective beta-blocker

Answer

Used in chronic congestive heart failure

Answer

It also has antioxidant and anti-inflammatory properties

Answer

Beta-blockers are started at low doses and gradually increased till maximum recommended dose

Question 2

Organic nitrates can lead to the development of tolerance when used chronically. Which of the following preparations is least likely to develop tolerance?

Accepted Answer

Sublingual nitroglycerine

Answer

Sustained release oral nitroglycerine

Answer

Transdermal nitroglycerine

Answer

Oral pentaerythritol tetranitrate

Question 3

Drugs associated with clinically useful or physiologically important positive inotropic effects include all of the following except?

Accepted Answer

Enalapril

Answer

Amrinone

Answer

Digoxin

Answer

Dobutamine

Question 4

Which of the following anti-angina drugs acts by inhibition of long-chain 3-ketoacyl coenzyme A thiolase?

Accepted Answer

Trimetazidine

Answer

Ivabradine

Answer

Ranolazine

Answer

Nicorandil

Question 5

Which of the following antihypertensive drugs inhibits the vesicular uptake of norepinephrine?

Accepted Answer

Reserpine

Answer

Propranolol

Answer

Prazosin

Answer

Guanithidine

Question 6

What is the primary effect of Nicotinic acid?

Accepted Answer

Increases HDL

Answer

Increases triglyceride synthesis

Answer

Treats Type II hyperlipoproteinemia

Answer

Decreases hydrolysis of VLDL

Question 7

Which ECG findings represent a characteristic manifestation of digitalis toxicity?

Accepted Answer

Atrial tachycardia with variable block

Answer

ST-segment depression

Answer

T-wave inversion

Answer

Atrial flutter

Question 8

Activation of which of the following receptors causes vasoconstriction?

Accepted Answer

ETa receptor

Answer

Nm receptor

Answer

M3 receptor

Answer

Nn receptor

Question 9

What is the drug available for the treatment of resistant cases of atrial fibrillation?

Accepted Answer

Amiodarone

Answer

Quinidine

Answer

Propranolol

Answer

Digoxin

Question 10

Which of the following statements regarding carvedilol is incorrect?

Accepted Answer

Its oral bioavailability is approximately 80%.

Answer

It is a beta-1, beta-2, and alpha-1 adrenergic receptor blocker.

Answer

It possesses antioxidant properties.

Answer

It is cardioprotective in patients with congestive heart failure.

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?